CVKD vs CNET Comparison

Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.

ZW Data Action Technologies Inc provides one-stop services for clients on its Omni-channel advertising, precision marketing, influencer marketing and data analysis management system. It also develops block-chain enabled web/mobile applications and provides Software-as-a-Service services for clients. In addition, it provides intellectual property licensing services. The company derives revenue from distributing the right to use search engine marketing service it purchased from key search engines to increase the sales conversion rate for clients business promotion on both mobile and computer searches; providing internet advertising and related marketing services for clients businesses; providing intellectual property licensing services; and providing Blockchain-based SaaS Services.